Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michel Delforge

Showing results (121-130 of 188) with videos related to

Pageof 19
Sort By:
Acta Clinica Belgica|April 27, 2026
Belgian recommendations for tissue diagnosis of amyloidosisAmélie Dendooven, Annelore Vandendriessche, Priyanka Joseph Koshy, et al.
The New England Journal of Medicine|February 10, 2023
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple MyelomaPaula Rodriguez-Otero, Sikander Ailawadhi, Bertrand Arnulf, et al.
Future Oncology (London, England)|April 23, 2024
Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myelomaPaula Rodriguez-Otero, Sikander Ailawadhi, Bertrand Arnulf, et al.
Journal of Geriatric Oncology|August 10, 2025
Prospective comparison between geriatric assessment and clinical evaluation in 200 newly diagnosed older adults with multiple myelomaJolien Raddoux, Cindy Kenis, Anneleen Vanhellemont, et al.
Leukemia|May 4, 2023
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)Evangelos Terpos, Pellegrino Musto, Monika Engelhardt, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 30, 2025
Outcomes of Patients With Extramedullary Disease in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma From the Pooled LocoMMotion and MoMMent StudiesPhilippe Moreau, María-Victoria Mateos, Hartmut Goldschmidt, et al.
Advances in Therapy|March 24, 2023
Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple MyelomaPhilippe Moreau, Niels W C J van de Donk, Michel Delforge, et al.
Haematologica|March 15, 2015
Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomideMichel Delforge, Leonard Minuk, Jean-Claude Eisenmann, et al.
Haematologica|April 16, 2016
Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myelomaKatja C Weisel, Meletios A Dimopoulos, Philippe Moreau, et al.
Haematologica|February 9, 2018
Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMTNico Gagelmann, Diderik-Jan Eikema, Simona Iacobelli, et al.
Pageof 19

Showing results (121-130 of 188) with videos related to

Sort By:
Pageof 19
Acta Clinica Belgica|April 27, 2026
Belgian recommendations for tissue diagnosis of amyloidosisAmélie Dendooven, Annelore Vandendriessche, Priyanka Joseph Koshy, et al.
The New England Journal of Medicine|February 10, 2023
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple MyelomaPaula Rodriguez-Otero, Sikander Ailawadhi, Bertrand Arnulf, et al.
Future Oncology (London, England)|April 23, 2024
Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myelomaPaula Rodriguez-Otero, Sikander Ailawadhi, Bertrand Arnulf, et al.
Journal of Geriatric Oncology|August 10, 2025
Prospective comparison between geriatric assessment and clinical evaluation in 200 newly diagnosed older adults with multiple myelomaJolien Raddoux, Cindy Kenis, Anneleen Vanhellemont, et al.
Leukemia|May 4, 2023
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)Evangelos Terpos, Pellegrino Musto, Monika Engelhardt, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 30, 2025
Outcomes of Patients With Extramedullary Disease in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma From the Pooled LocoMMotion and MoMMent StudiesPhilippe Moreau, María-Victoria Mateos, Hartmut Goldschmidt, et al.
Advances in Therapy|March 24, 2023
Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple MyelomaPhilippe Moreau, Niels W C J van de Donk, Michel Delforge, et al.
Haematologica|March 15, 2015
Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomideMichel Delforge, Leonard Minuk, Jean-Claude Eisenmann, et al.
Haematologica|April 16, 2016
Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myelomaKatja C Weisel, Meletios A Dimopoulos, Philippe Moreau, et al.
Haematologica|February 9, 2018
Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMTNico Gagelmann, Diderik-Jan Eikema, Simona Iacobelli, et al.
Pageof 19